Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry
- PMID: 22692814
- DOI: 10.1002/jbmr.1680
Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry
Abstract
We hypothesized that overall disease activity or the severity of involvement of individual disease compartments, as measured by clinical and surrogate markers, predict the risk of avascular osteonecrosis (AVN) or fractures in type 1 Gaucher disease (GD1). We applied our risk-set matched case-control method to identify four patient groups within the International Collaborative Gaucher Group (ICGG) Gaucher Registry based on the presence and absence of AVN and fractures. Characteristics of GD1 were examined by comparing the distributions of each risk factor in cases versus matched controls using conditional logistic regression to calculate adjusted odds ratios (OR). Potential risk factors included hematological and visceral parameters, GD1 biomarkers, white blood cells, GBA1 genotype, and spine and femur dual-energy X-ray absorptiometry (DXA) Z-scores. In the total population of 5894 ICGG Gaucher Registry patients, 544 experienced at least one episode of AVN; 2008 reported no history of AVN. Clinical and surrogate markers of disease activity were similar in patients with and without AVN; patients with AVN were 1.6 times more likely to be anemic compared to matched controls (OR = 1.59; 95% confidence interval [CI], 1.06-2.38, p < 0.05). For fractures, 319 patients suffered fractures and 1233 had no prior history of fractures. Clinical and surrogate markers of disease in patients with and without fractures were similar, except for mean lumbar spine DXA Z-scores. Among patients with fractures, 49.3% had DXA Z-scores ≤ -1 compared to 31.0% in the control group. Compared to controls with Z-scores > -1.0, GD1 patients exhibiting Z-scores ≤ -1 had an OR of 5.55 (95% CI, 1.81-17.02, p < 0.01) for fracture. In GD1, after controlling for gender, year of birth, treatment status, and splenectomy status, we identified new risk factors for AVN and fractures. Concurrent anemia was associated with an increased risk for AVN. Low bone mineral density of the lumbar spine was a strong risk factor for fractures of the spine and femur in GD1.
Copyright © 2012 American Society for Bone and Mineral Research.
Similar articles
-
Reducing selection bias in case-control studies from rare disease registries.Orphanet J Rare Dis. 2011 Sep 12;6:61. doi: 10.1186/1750-1172-6-61. Orphanet J Rare Dis. 2011. PMID: 21910867 Free PMC article.
-
Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.Br J Haematol. 2009 Nov;147(4):561-70. doi: 10.1111/j.1365-2141.2009.07872.x. Epub 2009 Sep 3. Br J Haematol. 2009. PMID: 19732054 Free PMC article.
-
Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.Blood Cells Mol Dis. 2011 Jan 15;46(1):66-72. doi: 10.1016/j.bcmd.2010.10.011. Epub 2010 Nov 26. Blood Cells Mol Dis. 2011. PMID: 21112800 Free PMC article.
-
Velaglucerase alfa for the management of type 1 Gaucher disease.Clin Ther. 2012 Feb;34(2):259-71. doi: 10.1016/j.clinthera.2011.12.017. Epub 2012 Jan 20. Clin Ther. 2012. PMID: 22264444 Review.
-
Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry.Am J Hematol. 2015 Jul;90 Suppl 1:S12-8. doi: 10.1002/ajh.24063. Am J Hematol. 2015. PMID: 26096741 Review.
Cited by
-
Achievement of therapeutic goals with low-dose imiglucerase in Gaucher disease: a single-center experience.Adv Hematol. 2013;2013:151506. doi: 10.1155/2013/151506. Epub 2013 Oct 28. Adv Hematol. 2013. PMID: 24285960 Free PMC article.
-
Proprioceptive Neuromuscular Facilitation (PNF)-Integrated Gait Rehabilitation Following Total Hip Arthroplasty.Cureus. 2024 Apr 8;16(4):e57854. doi: 10.7759/cureus.57854. eCollection 2024 Apr. Cureus. 2024. PMID: 38721165 Free PMC article.
-
Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.Am J Hematol. 2015 Jul;90(7):584-91. doi: 10.1002/ajh.24012. Am J Hematol. 2015. PMID: 25801797 Free PMC article. Clinical Trial.
-
Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat.Mol Genet Metab Rep. 2020 May 30;24:100606. doi: 10.1016/j.ymgmr.2020.100606. eCollection 2020 Sep. Mol Genet Metab Rep. 2020. PMID: 32509532 Free PMC article.
-
Evaluation of an imaging biomarker, Dixon quantitative chemical shift imaging, in Gaucher disease: lessons learned.J Inherit Metab Dis. 2014 Nov;37(6):1003-11. doi: 10.1007/s10545-014-9726-3. Epub 2014 Jun 13. J Inherit Metab Dis. 2014. PMID: 24924293 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical

